News

Depression linked to accelerated cognitive decline in diabetes


 

FROM JAMA PSYCHIATRY

The ACCORD-MIND study was funded through an intra-agency agreement between the National Institute on Aging; the National Heart, Lung, and Blood Institute; and the National Institute on Aging Intramural Research Program. Study drugs, equipment, and/or supplies were provided by Abbott Laboratories, Amylin Pharmaceuticals, AstraZeneca, Bayer HealthCare, Closer Healthcare, GlaxoSmithKline, King Pharmaceuticals, Merck, Novartis, Novo Nordisk, Omron Healthcare, Sanofi-Aventis, and Schering-Plough.

Pages

Recommended Reading

Duloxetine proves beneficial in elderly GAD
MDedge Internal Medicine
Novel intranasal antidepressant shows results after 1 week
MDedge Internal Medicine
New measure of depression remission looks promising
MDedge Internal Medicine
Selegiline transdermal system promising for social phobia
MDedge Internal Medicine
Low-dose paroxetine approved for hot flashes
MDedge Internal Medicine
Aphasic stroke patients' mood lifted by behavioral therapy
MDedge Internal Medicine
Levomilnacipran SR for major depression also improves attention deficits
MDedge Internal Medicine
Suicide risk in the military similar to that in civilian populations
MDedge Internal Medicine
CRTC1 polymorphisms affect BMI, novel study finds
MDedge Internal Medicine
Depression, some antidepressants linked to high C. difficile risk
MDedge Internal Medicine